Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

Tytuł :
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
Autorzy :
Velikova, G
Thanarajasingam, G
Minasian, LM
Baron, F
Cavalli, F
De Claro, RA
Dueck, AC
El-Galaly, TC
Everest, N
Geissler, J
Gisselbrecht, C
Gribben, J
Horowitz, M
Ivy, SP
Jacobson, CA
Keating, A
Kluetz, PG
Krauss, A
Kwong, YL
Little, RF
Mahon, F-X
Matasar, MJ
Mateos, M-V
McCullough, K
Miller, RS
Mohty, M
Moreau, P
Morton, LM
Nagai, S
Rule, S
Sloan, J
Sonneveld, P
Thompson, CA
Tzogani, K
Van Leeuwen, FE
Villa, D
Wingard, JR
Wintrich, S
Seymour, JF
Habermann, TM
Pokaż więcej
Temat :
Hematology [Human health sciences]
Hématologie [Sciences de la santé humaine]
Źródło :
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet. Haematology, 5, 563-598., United KingdomElsevier. (2018).
Wydawca :
Elsevier, 2018.
Rok publikacji :
2018
Opis pliku :
application/pdf
Język :
English
ISSN :
2352-3026
Numer akcesji :
edsair.dedup.wf.001..8f3985d69fb4f4ea0e8716a7531cc557
Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma has improved markedly. This improvement is a result of substantial changes in disease management strategies in these malignancies. Several haematological malignancies are now chronic diseases that are treated with continuously administered therapies that have unique side-effects over time. In this Commission, an international panel of clinicians, clinical investigators, methodologists, regulators, and patient advocates representing a broad range of academic and clinical cancer expertise examine adverse events in haematological malignancies. The issues pertaining to assessment of adverse events examined here are relevant to a range of malignancies and have been, to date, underexplored in the context of haematology. The aim of this Commission is to improve toxicity assessment in clinical trials in haematological malignancies by critically examining the current process of adverse event assessment, highlighting the need to incorporate patient-reported outcomes, addressing issues unique to stem-cell transplantation and survivorship, appraising challenges in regulatory approval, and evaluating toxicity in real-world patients. We have identified a range of priority issues in these areas and defined potential solutions to challenges associated with adverse event assessment in the current treatment landscape of haematological malignancies.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies